VistaGen Therapeutics Inc (VTGN)

[stocktrademan]

$VSTA recent news/filings

bullish

## source: finance.yahoo.com

Thu, 18 Jun 2015 15:29:50 GMT ~ Buy VistaGen On AV-101 Profile, Chardan Analyst Says


read full: http://finance.yahoo.com/news/buy-vistagen-av-101-profile-152950434.html
*********************************************************

Thu, 18 Jun 2015 12:12:32 GMT ~ Coverage initiated on VistaGen by Chardan Capital Markets


read full: http://finance.yahoo.com/q/ud?s=VSTA
*********************************************************

Tue, 16 Jun 2015 13:02:06 GMT ~ VISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equi


read full: http://biz.yahoo.com/e/150616/vsta8-k.html
*********************************************************

Fri, 22 May 2015 21:24:37 GMT ~ VISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equi


read full: http://biz.yahoo.com/e/150522/vsta8-k.html
*********************************************************

Wed, 13 May 2015 21:20:39 GMT ~ VISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equi


read full: http://biz.yahoo.com/e/150513/vsta8-k.html
*********************************************************

$VSTA charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$VSTA company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/VSTA/company-info
Ticker: $VSTA
OTC Market Place: OTCQB
CIK code: 0001411685
Company name: VistaGen Therapeutics, Inc.
Company website: http://www.vistagen.com
Incorporated In: NV, USA

Business Description: VistaGen Therapeutics (VSTA) - New Generation Antidepressant and Drug Rescue Using Stem Cell TechnologyVistaGen Therapeutics is a clinical-stage biopharmaceutical company developing innovative medicine for depression, conditions of the central nervous system, and cancer. AV-101 is VistaGen?s orally-active NMDA receptor modulator entering Phase 2 clinical development in the U.S. for the treatment of Major Depressive Disorder (MDD), a chronic, pervasive feeling of utter unhappiness and suffering which impairs daily functioning. The WHO estimates that MDD affects 350 million worldwide, including 6.7% of U.S. adults. Agents that have formed the mainstay of antidepressant therapy in the U.S. and other pharmaceutical markets for the past 50 years have a mechanism of action requiring many weeks to achieve therapeutic benefits. This multi-week lag in onset of benefits is a widely recognized therapeutic limitation of existing antidepressant agents, resulting in worsening depression and high risk of suicidal thoughts and behaviors, and highlighting the urgent medical need for a new generation of safe, rapid-acting antidepressant agents. In clinical trials conducted by Dr. Carlos Zarate and others at the NIH?s National Institute of Mental Health (NIMH), ketamine, an NMDA receptor antagonist, produced robust and rapid antidepressant effects in treatment-resistant MDD patients. Although the potential for widespread use of ketamine is severely limited by its potential for abuse, psychosis-like side effects, schizophrenia-like side effects, and practical challenges of intravenous administration, the relatively recent discovery of ketamine?s rapid-acting antidepressant effects revolutionized thinking about antidepressant medicine and ushered in development of a new generation of drug candidates, such as AV-101, with a fundamentally novel mechanism of action compared to existing antidepressant agents. Like ketamine, AV-101 is an NMDA receptor antagonist. However, unlike ketamine, by binding to the glycine-B site of the NMDA receptor, AV-101 modulates (i.e. it down-regulates) NMDA receptor channel activity, but does not block it, as ketamine does. Based on its preclinical efficacy data, novel mechanism of action, clinical safety in Phase 1 studies, and oral delivery, VistaGen?s AV-101 has the potential to achieve the rapid-acting antidepressant effects of ketamine without any of ketamine?s serious side effects. In two NIH-funded Phase 1 safety studies, AV-101 was well tolerated, without any serious adverse events. There were no signs of sedation, hallucinations or the schizophrenia-like side effects often associated with ketamine and other NMDA channel blockers. VistaGen has signed a letter of intent to enter into a Cooperative Research and Development Agreement (CRADA) with the NIMH to collaborate with Dr. Zarate on an NIH-funded Phase 2 clinical study of AV-101 in MDD. Dr. Zarate, the NIMH?s Chief of the Section on the Neurobiology and Treatment of Mood Disorders and Chief of Experimental Therapeutics and Pathophysiology, will be the Principal Investigator for the Phase 2 MDD study, which is expected to begin in the first half of 2015 and be completed at the end of 2015. In addition to AV-101, using human heart and liver cells produced with proprietary stem cell technology, VistaGen has developed CardioSafe 3D? and LiverSafe 3D?, customized bioassay systems used to predict heart toxicity and liver toxicity of new drug candidates before they are tested in animal or human studies. VistaGen is focused on using these bioassay systems for drug rescue to produce proprietary new chemical entities (NCEs) to expand its pipeline with safer variants of drug rescue candidates previously optimized for efficacy by pharmaceutical companies and others but terminated prior to FDA approval due to heart or liver toxicity. VistaGen?s current drug rescue program is focused on a novel therapy for cancer.Less >>

$VSTA share structure

## source: otcmarkets.com

Market Value: $14,735,280 a/o Jun 17, 2015
Shares Outstanding: 1,473,528 a/o Feb 13, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001

$VSTA extra dd links

Company name: VistaGen Therapeutics, Inc.
Company website: http://www.vistagen.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/VSTA/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/VSTA/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=VSTA+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=VSTA+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=VSTA+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/VSTA/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/VSTA/news - http://finance.yahoo.com/q/h?s=VSTA+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/VSTA/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/VSTA/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/VSTA/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/VSTA/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/VSTA/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/VSTA/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/VSTA/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/VSTA/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=VSTA+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/VSTA
DTCC (dtcc.com): http://search2.dtcc.com/?q=VistaGen+Therapeutics%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=VistaGen+Therapeutics%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=VistaGen+Therapeutics%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.vistagen.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.vistagen.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.vistagen.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/VSTA/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/VSTA
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/VSTA/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/VSTA/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/VSTA/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001411685&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/VSTA/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/VSTA/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/VSTA/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/VSTA/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=VSTA&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=VSTA
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/VSTA/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=VSTA+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=VSTA+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=VSTA
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=VSTA
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=VSTA+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/VSTA/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=VSTA+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/VSTA.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=VSTA
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/VSTA/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/VSTA/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/VSTA/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/VSTA/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/VSTA
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/VSTA
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/VSTA:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=VSTA
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=VSTA



$VSTA DD Notes ~ http://www.ddnotesmaker.com/VSTA